SleepWell:精神病超高危青少年睡眠问题的靶向心理治疗可行性随机对照试验
该平行组、单盲随机对照可行性试验在英格兰两家NHS信托机构纳入40名14-25岁精神病超高危且存在睡眠问题的青少年,比较SleepWell睡眠心理治疗联合常规照护与单纯常规照护。结果显示试验可行、治疗接受度高,SleepWell组失眠严重度在3个月和9个月均较对照组显著下降,但样本量小,尚需确定性多中心试验验证。
要点
- 精神病超高危青少年中开展睡眠靶向心理治疗的随机对照试验具有可行性且治疗接受度高。
- 不良事件少且均未判定与试验治疗或程序相关,但仍需多中心确定性试验验证临床疗效。
核心结论
- 在精神病超高危青少年中开展睡眠靶向心理治疗的随机对照可行性试验是可行的,并初步显示失眠严重度持续下降。
研究设计与样本
- 平行组、单盲随机对照可行性试验,在英格兰两家NHS信托机构开展,纳入14-25岁精神病超高危且当前存在睡眠问题的患者。
- 共筛查67人,招募40人,按1:1随机分配至SleepWell睡眠心理治疗联合常规照护组(21人)或单纯常规照护组(19人)。
- SleepWell治疗为个体形式,约8次、每次1小时,持续12周;评估在0、3、9个月进行,评估者对分组设盲。
主要发现
- 所有参与者至少完成一次随访,39人(98%)完成3个月和9个月的主要结局评估。
- SleepWell组21人中有20人(95%)接受了至少4次治疗的预设最低剂量;AARP治疗接受度评分中位数为48(IQR 46-48;n=17;最高可能得分48)。
- 6名参与者共报告8起不良事件(常规照护组2人[11%],SleepWell组4人[19%]);SleepWell组1起因躯体健康问题住院的严重不良事件,常规照护组1人转为精神病,均未判定与试验治疗或程序相关。
关键数值与推荐
- 入组标准包括年龄14-25岁、精神卫生服务患者、经CAARMS评估为精神病超高危、当前存在睡眠问题且ISI自评≥15分。
- 主要可行性结局包括识别、招募和保留的患者数、治疗接受度和数据完成情况;治疗接受度用AARP测量。
- 初步临床主要结局为3个月和9个月时ISI评估的失眠严重度,按随机分组进行意向性分析。
临床怎么用
- 对于精神病超高危且伴失眠的青少年,可考虑在常规照护基础上提供结构化睡眠心理治疗,但当前证据仅为可行性试验级别。
局限性
- 本研究为单中心可行性试验,样本量小(40人),主要目的为评估可行性与初步疗效,不足以支持确定性临床结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sleep disturbance is common and problematic for young people at ultra-high risk of psychosis. Sleep disruption is a contributory causal factor in the occurrence of mental health problems, including psychotic experiences, anxiety, and depression. The implication is that treating sleep problems might have additional benefits on mental health outcomes in individuals at high risk. The present study had two aims: first, to establish the feasibility and acceptability of a randomised controlled trial to treat sleep problems with the aim of reducing psychotic experiences in young people at ultra-high risk of psychosis; and second, to provide proof of concept of the clinical efficacy of the treatment. METHODS: We did a parallel group, single-blind, randomised controlled feasibility trial in two National Health Service trusts in England. Eligible participants were aged 14-25 years, a patient of mental health services, assessed as being at ultra-high risk of psychosis on the Comprehensive Assessment of At-Risk Mental States, and having current sleep problems (score of ≥15 on the self-report Insomnia Severity Index [ISI]). Participants were randomly assigned (1:1) to either a targeted psychological therapy for sleep problems (SleepWell) plus usual care or usual care alone via an automated online system, with non-deterministic minimisation that balanced participants for ISI score and referring service. The SleepWell therapy was delivered on an individual basis in approximately eight 1-h sessions over 12 weeks. Assessments were done at 0, 3, and 9 months, with trial assessors masked to treatment allocation. The key feasibility outcomes were the numbers of patients identified, recruited, and retained, treatment uptake, and data completion. Treatment acceptability was measured with the Abbreviated Acceptability Rating Profile (AARP). In preliminary clinical assessments, the primary clinical outcome was insomnia at 3 and 9 months assessed with the ISI, reported by randomised group (intention-to-treat analysis). Safety was assessed in all randomly assigned participants. The trial was prospectively registered on ISRCTN, 85601537, and is completed. FINDINGS: From Nov 18, 2020, to Jan 26, 2022, 67 young people were screened, of whom 40 (60%) at ultra-high risk of psychosis were recruited. Mean age was 16·9 years (SD 2·5; range 14-23), and most participants identified as female (n=19 [48%]) or male (n=19 [48%]) and as White (n=32 [80%]). 21 participants were randomly assigned to SleepWell therapy plus usual care and 19 to usual care alone. All participants provided data on at least one follow-up visit. 39 (98%) of 40 participants completed the primary outcome assessment at 3 and 9 months. 20 (95%) of 21 participants assigned to SleepWell therapy received the prespecified minimum treatment dose of at least four sessions. The median treatment acceptability score on the AARP was 48 (IQR 46 to 48; n=17; maximum possible score 48). At the post-intervention follow-up (3 months), compared with the usual care alone group, the SleepWell therapy group had a reduction in insomnia severity (ISI adjusted mean difference -8·12 [95% CI -11·60 to -4·63]; Cohen's d=-2·67 [95% CI -3·81 to -1·52]), which was sustained at 9 months (ISI adjusted mean difference -5·83 [-9·31 to -2·35]; Cohen's d=-1·91 [-3·06 to -0·77]). Among the 40 participants, eight adverse events were reported in six participants (two [11%] participants in the usual care group and four [19%] participants in the SleepWell therapy group). One serious adverse event involving hospital admission for a physical health problem was reported in the SleepWell therapy group, and one patient in the usual care alone group transitioned to psychosis. None of these events were classed as being related to trial treatment or procedures. INTERPRETATION: A randomised controlled trial of a targeted psychological sleep therapy for young people at ultra-high risk of psychosis is feasible. Patients can be retained in the trial and assessments done by masked assessors. Uptake of the sleep therapy was high, and we found preliminary evidence of sustained reductions in sleep problems. A definitive multicentre trial is now needed. FUNDING: NIHR Research for Patient Benefit and NIHR Oxford Health Biomedical Research Centre.
引用
- Waite F, Černis E, Kabir T, et al. A targeted psychological treatment for sleep problems in young people at ultra-high risk of psychosis in England (SleepWell): a parallel group, single-blind, randomised controlled feasibility trial. Lancet Psychiatry. 2023. PMID: 37562423. doi:10.1016/S2215-0366(23)00203-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。